MAP2K7 and cholangiocarcinoma: In the ROAR basket trial (a Phase II study), the efficacy of the RAF inhibitor dabrafenib combined with the MEK inhibitor trametinib was evaluated in 178 patients with BRAF V600E-mutated solid tumors, including those with refractory CCA [153].